The EU Commission fines pharmaceutical companies in pay-to-delay case (Servier)

European Commission fines pharmaceutical companies in pay-to-delay case* Last 9 July the European Commission (“Commission”) fined (see press releases here and here) French pharmaceutical company Servier and five generics manufacturers ( Niche/Unichem, Matrix (now part of Mylan), Teva, Krka and Lupin) for breaches of the rules on restrictive agreements (Article 101 of the Treaty on the Functioning of the European Union or “TFEU”) and on abuse of a dominant position (Article 102 TFEU). The fines imposed totaled Euro 427.7 million, of which Euro 330 million were imposed on

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Gabriele Accardo, The EU Commission fines pharmaceutical companies in pay-to-delay case (Servier), 9 July 2014, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 72160

Visites 264

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues